Download PDFPDF
Original article
Therapeutic potential of valproic acid for retinitis pigmentosa
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Author Response Re: "Need to further investigate the efficacy of valproic acid therapy in retinal degenerative disorders" letter
    • Radouil Tzekov
    • Other Contributors:
      • , Christine Clemson, Mark Krebs, Jenna Checchi, Shalesh Kaushal

    Dear Editor,

    We appreciate the interest of Dr. Kahn and Dr. Philip [1] in our paper describing pilot results from a retrospective study in patients with retinitis pigmentosa (RP) treated with valproic acid (VPA) [2], and we would like to comment on the points raised by them.

    Length of treatment. As mentioned in our recent reply to another letter regarding the same article [3], the length of treatment...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Need to further investigate the efficacy of valproic acid therapy in retinal degenerative disorders
    • Sujoy Khan, Consultant Immunologist, Frimley Park Hospital NHS Foundation Trust, Frimley, Surrey, GU16 7UJ, UK
    • Other Contributors:
      • Swetha Philip, Consultant Ophthalmologist, Christian Medical College & Hospital, Vellore, India

    Dear Editor,

    We have a few concerns on the report by Clemson CM et al on the efficacy of valproic acid (VPA) in 7 patients with retinitis pigmentosa (RP) [1]. Was the time period of 6 months for using VPA the maximum time that was allowed by the institutional review boards? The degree to which the retina was affected by RP was not mentioned in each case (either in the form of photographic evidence or by electro...

    Show More
    Conflict of Interest:
    None declared.